Stockscreener 앱 받기
2.23
1.76%
-0.04
시간 외 거래:
2.21
-0.02
-0.90%
전일 마감가:
$2.27
열려 있는:
$2.27
하루 거래량:
70,636
Relative Volume:
1.46
시가총액:
$74.75M
수익:
$6.21M
순이익/손실:
$-19.92M
주가수익비율:
-2.1238
EPS:
-1.05
순현금흐름:
$-16.76M
1주 성능:
-9.90%
1개월 성능:
-12.89%
6개월 성능:
-15.21%
1년 성능:
-8.61%
1일 변동 폭
$2.17
$2.275
1주일 범위
$1.99
$2.3342
52주 변동 폭
$1.99
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
명칭
InspireMD Inc.
전화
972 3 6917691
주소
4 Menorat Hamaor Street, Tel Aviv
NSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.23 | 74.75M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2016-01-07 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 개시 | Oppenheimer | Outperform |
InspireMD Inc. 주식(NSPR)의 최신 뉴스
InspireMD’s embolic prevention system gains CE Mark approval - Yahoo Finance
InspireMD receives CE mark approval for CGuard Prime stent system By Investing.com - Investing.com South Africa
InspireMD Gains CE Mark for Stroke Device CGuard Prime - MarketScreener
InspireMD Gains CE Mark Approval for CGuard® Prime - TipRanks
InspireMD announces CE Mark approval for CGuard Prime EPS - TipRanks
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - The Manila Times
InspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent System - Nasdaq
InspireMD Announces CE Mark Approval for CGuard® Prime - GlobeNewswire
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - GlobeNewswire Inc.
Millennium Management LLC Has $867,000 Position in InspireMD, Inc. (NYSE:NSPR) - Defense World
Medical device company appoints CFO - The Business Journals
InspireMD appoints Michael Lawless CFO - MSN
Northern Trust Corp Acquires 24,452 Shares of InspireMD, Inc. (NYSE:NSPR) - Defense World
InspireMD names Michael Lawless as new CFO By Investing.com - Investing.com South Africa
InspireMD Appoints Michael Lawless as CFO - marketscreener.com
InspireMD (NSPR) Announces New CFO Appointment | NSPR Stock News - GuruFocus
InspireMD names Michael Lawless as new CFO - Investing.com Australia
InspireMD Holds Annual Stockholders Meeting and Elections - TipRanks
InspireMD CFO Craig Shore to depart, Michael Lawless to succeed - TipRanks
InspireMD Appoints New CFO Amidst Strategic Expansion - TipRanks
InspireMD Announces Appointment Of Michael Lawless As Chief Financial Officer - marketscreener.com
InspireMD Taps Healthcare Veteran Michael Lawless as CFO Ahead of Major US Launch - Stock Titan
Inspire Medical Systems (NYSE:INSP) and InspireMD (NYSE:NSPR) Head-To-Head Contrast - Defense World
OrthoPediatrics (NASDAQ:KIDS) versus InspireMD (NYSE:NSPR) Critical Review - Defense World
Piper Sandler Lowers InspireMD (NYSE:NSPR) Price Target to $4.00 - Defense World
InspireMD Inc. Reports Q1 2025 Financial Results - MSN
InspireMD outlines Q3 2025 FDA approval target for CGuard Prime - MSN
InspireMD Inc’s Earnings Call: Growth Amid Challenges - MSN
InspireMD (NSPR) Sees Price Target Reduction by Piper Sandler | - GuruFocus
InspireMD price target lowered to $4 from $4.50 at Piper Sandler - TipRanks
Piper Sandler cuts InspireMD stock price target to $4.00 By Investing.com - Investing.com South Africa
Piper Sandler cuts InspireMD stock price target to $4.00 - Investing.com Australia
InspireMD (NSPR) Price Target Reduced, FDA Approval Timeline Adj - GuruFocus
InspireMD initiated with a Buy at Lake Street - TipRanks
InspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Call Transcript - Insider Monkey
InspireMD Inc (NSPR) Q1 2025 Earnings Report Preview: What To Lo - GuruFocus
InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges By GuruFocus - Investing.com Canada
Earnings call transcript: InspireMD Q1 2025 shows mixed results - Investing.com
InspireMD earnings beat by $0.09, revenue fell short of estimates - Investing.com Canada
InspireMD reports Q1 EPS (22c) vs (21c) last year - TipRanks
InspireMD (NSPR) Posts Slight Increase in Q1 Revenue | NSPR Stoc - GuruFocus
InspireMD Inc (NSPR) Q1 2025 Earnings: Revenue of $1.53M Beats E - GuruFocus
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic - NewsBreak: Local News & Alerts
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic By Stocktwits - Investing.com India
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
InspireMD Reports First Quarter 2025 Financial Results - The Manila Times
InspireMD, Inc. Reports Q1 2025 Financial Results and Anticipates FDA Approval for CGuard™ Prime Carotid Stent System - Nasdaq
Renaissance Technologies LLC Invests $27,000 in InspireMD, Inc. (NYSE:NSPR) - Defense World
INSPIREMD Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com - Defense World
InspireMD Inc. (NSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.52%
0.92%
자본화:
|
볼륨(24시간):